TSC research including Research Round Up – a quarterly summary of some of the most important TSC-related research from Australia and around the world.
We are pleased to share news that Everolimus (Afinitor) for epilepsy has been given a positive recommendation by the pharmaceutical benefits advisory committee (PBAC). This is a recommendation to the Federal Health Minister to add this medicine to the pharmaceutical … Read More
Today we celebrate the academic publication of results from the Treatment trial. This research developed a topical cream to treat the small tumours that grow on the face of people with tuberous sclerosis. While these tumours, called angiofibromas, do … Read More
Invitation to TSC families in NSW and ACT to participate in this focus group study.
Dr Denise Chan spoke with TSA’s General Manager, Clare Stuart First of all, congratulations on your recent travel award to the International TSC Research Conference. What was your TSC research project about? Thanks! I am a paediatric neurology fellow at … Read More
A selection of recently published articles with a focus on high impact and Australian TSC research. Summaries written by Kate Fessey and Clare Stuart. This article was first published in the October 2016 issue of Reach Out, TSA’s twice-yearly magazine. … Read More
From an interview with Dr Simon Harvey, paediatric neurologist and director of the Children’s Epilepsy Program at Royal Children’s Hospital, Melbourne. This article was first published in the October 2016 issue of Reach Out, TSA’s twice-yearly magazine. What is epilepsy … Read More
From an interview with Dr Kate Riney, paediatric neurologist and TSC clinic lead at Lady Cilento Children’s Hospital, Brisbane. This article was first published in the October 2016 issue of Reach Out, TSA’s twice-yearly magazine. Can you describe this new … Read More
We’ve updated our information on the availability of this new treatment for facial angiofibromas.
The American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS) have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age and is associated with … Read More
Topical Rapamycin is an experimental treatment for facial angiofibromas, which affect the majority of people with Tuberous Sclerosis. A formal clinical trial, funded by generous donors to Tuberous Sclerosis Australia, has completed at Sydney Children’s Hospital which aims to provide … Read More
